Literature DB >> 1317667

A histiocyte-specific marker in the diagnosis of malignant fibrous histiocytoma. Use of monoclonal antibody KP-1 (CD68)

S W Binder1, J W Said, I P Shintaku, G S Pinkus.   

Abstract

KP-1 (CD68) is a recently described monoclonal antibody to a cytoplasmic epitope present on tissue histiocytes and macrophages. To determine the specificity and sensitivity of this marker in the evaluation of cases of malignant fibrous histiocytoma (MFH), this reagent and a panel of commercially antibodies were used to stain formalin-fixed paraffin sections from 25 cases of MFH and 25 other tumors, including a variety of soft-tissue sarcomas. Eighteen of 25 cases of MFH stained for KP-1 (72%), whereas all other tumors were negative, including 12 cases of pleomorphic soft-tissue sarcoma other than MFH. The percentage of tumor cells staining for KP-1 varied. In 11 cases KP-1 was only focally present, but staining was of a high intensity and associated with minimal nonspecific or background staining. Pleomorphic histiocytic cells and spindle cells from storiform tumors were strongly decorated with antibodies to KP-1 in most cases, and antigen also was present on tumor giant cells. Although alpha-1-antitrypsin and alpha-1-chymotrypsin stained a higher percentage of cases of MFH (92%), immunoreactivity for these markers also was noted in other tumors. Because of its specificity as a histiocyte marker, KP-1 is a useful component in a panel of antibodies for the characterization of soft-tissue sarcomas and the diagnosis of MFH.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317667     DOI: 10.1093/ajcp/97.6.759

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Retroperitoneal malignant fibrous histiocytoma.

Authors:  D Répássy; S Csata; G Sterlik; P Hazslinszky
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

2.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

3.  Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency.

Authors:  Jinhyang Choi; Stephen J Curtis; David M Roy; Andrea Flesken-Nikitin; Alexander Yu Nikitin
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

4.  Primary malignant fibrous histiocytoma of the kidney: report of a case and literature review.

Authors:  Çağatay Göğüş; Mehmet İlker Gökce; Evren Süer; Özden Tulunay; Mut Şafak
Journal:  Turk J Urol       Date:  2013-09

5.  Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy.

Authors:  Kiran Gollapudi; Colette Galet; Tristan Grogan; Hong Zhang; Jonathan W Said; Jiaoti Huang; David Elashoff; Stephen J Freedland; Matthew Rettig; William J Aronson
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

6.  Genipin guides and sustains the polarization of macrophages to the pro-regenerative M2 subtype via activation of the pSTAT6-PPAR-gamma pathway.

Authors:  Ilaha Isali; Phillip McClellan; Eswar Shankar; Sanjay Gupta; Mukesh Jain; James M Anderson; Adonis Hijaz; Ozan Akkus
Journal:  Acta Biomater       Date:  2021-07-02       Impact factor: 10.633

7.  Benign fibrous histiocytoma: A rare case involving jaw bone.

Authors:  Hitesh Shoor; Keerthilatha M Pai; Ankur Kaur Shergill; Abhay Taranath Kamath
Journal:  Contemp Clin Dent       Date:  2015-09

8.  Rare pancreatic metastasis of undifferentiated pleomorphic sarcoma originating from the pelvis: A case report.

Authors:  Manato Ohsawa; Yoshihiro Mikuriya; Koji Ohta; Minoru Tanada; Noriaki Yamamoto; Norihiro Teramoto; Masahiro Kiyono; Shinsuke Sugihara
Journal:  Int J Surg Case Rep       Date:  2020-02-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.